1. Sensitivity of a Preclinical Alzheimer’s Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer’s disease
- Author
-
Yen Ying Lim, Joanne Roberston, Victor L. Villemagne, Lisa Bransby, Christopher Fowler, Colin L. Masters, David Ames, Paul Maruff, Olivier Salvado, Karra Harrington, and Peter J. Snyder
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Amyloid β ,Amyloid beta ,Neuroimaging ,Disease ,Neuropsychological Tests ,Sensitivity and Specificity ,050105 experimental psychology ,Amyloid beta-Protein Precursor ,03 medical and health sciences ,0302 clinical medicine ,Alzheimer Disease ,Internal medicine ,medicine ,Humans ,Cognitive Dysfunction ,0501 psychology and cognitive sciences ,Longitudinal Studies ,Prospective Studies ,Cognitive decline ,Life Style ,Aged ,Aged, 80 and over ,Mini–Mental State Examination ,biology ,medicine.diagnostic_test ,05 social sciences ,Australia ,Cognition ,Middle Aged ,Mental Status and Dementia Tests ,Prognosis ,medicine.disease ,Clinical neurology ,Clinical Psychology ,Neurology ,Positron-Emission Tomography ,Disease Progression ,biology.protein ,Female ,Neurology (clinical) ,Alzheimer's disease ,Psychology ,Biomarkers ,030217 neurology & neurosurgery - Abstract
Introduction: Preclinical Alzheimer’s disease (AD) is characterized by amyloid-related cognitive decline. Reduction in this decline is used to determine the efficacy of drug therapies designed to f...
- Published
- 2019
- Full Text
- View/download PDF